News | EP Lab | August 03, 2021

Spinal Cord Stimulation Helps Suppress AF in CABG Patients

HRS 2021 late-breaker shows another method to reduce atrial fibrillation in coronary bypass patients

emporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS).  #HRS21 #HRS2021

August 4, 2021 — Temporary Spinal cord stimulation (SCS) was effective in suppressing post-operative atrial fibrillation (AF) after coronary artery bypass (CAGB) surgery CABG without any adverse events in a randomized pilot study. The TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF) study was presented as a late-breaking study presented at the 2021 Heart Rhythm meeting, the annual conference of the Heart Rhythm Society (HRS)

Spinal cord stimulation has been shown to be effective in the treatment of chronic pain and intractable angina pectoris. Recently, animal studies have demonstrated that SCS can also suppress AF, explained presenter Alexander B. Romanov, M.D., Ph.D., FHRS, E. Meshalkin National Medical Research Center of the Ministry of Health, Novosibirsk, Russia. He said this study looked at its application in human patients who underwent CABG to see if it could suppress AF in this patient population.

The study included 52 patients with indications for coronary artery bypass grafting (CABG) and history of paroxysmal AF were randomized to 2 groups: CABG plus standard medical therapy (MED) with beta-blockers (n=26, Control group) and CABG plus MED plus percutaneous lead placement for temporary SCS (n=26, SCS group). In the SCS group under local anesthesia and with fluoroscopic guidance, temporary leads were placed at C7-T4 level according to patient’s sense of paresthesia and connected to a SC stimulator externally fixed on patient’s chest. Temporary SCS was begun 3 days before elective CABG, deactivated during surgery, reactivated in the intensive care unit after CABG, and continued for 7 days at which time the leads were removed Continuous external ECG monitoring was performed for 30 days after CABG in all patients. These primary objectives were tested over the 30-day post-operative period: 1) occurrence of adverse events, including death, stroke or TIA, myocardial infarction and kidney injury; and 2) occurrence of AF or any atrial tachyarrhythmia lasting ≥ 30 seconds.

Percutaneous lead placement for temporary SCS was successfully performed in all 26 patients before CABG without any complications. There were no any adverse events related to temporary SCS in any patient throughout follow-up. There were no significant differences in CK-MB and creatinine levels between groups (p=0.1 and 0.2, respectively) as well as other typical CABG-related complications (p>0.05). Post-operative AF occurred in 8 (30.7%) of
26 patients in the Control group versus only 1 (3.8%) of 26 patients in the SCS group (p=0.012, log-rank test, Figure).

Researchers said further studies of SCS with larger samples should be conducted to test its clinical value as a peri-operative intervention.

Find additional HRS 2021 late breaking trials

Find more EP device news

Find more HRS 2021 conference news

 

Related Content

Ablation and Biventricular Pacing Boosts Survival in Selected Atrial Fibrillation Patients in APAF-CRT Trial. #ESC #ESCcongress
News | Atrial Fibrillation | September 13, 2021
September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate contro
The Medtronic Linq II implantable cardiac monitor.

The Medtronic Linq II implantable cardiac monitor.

News | Atrial Fibrillation | September 08, 2021
September 8, 2021 — Continuous heart rhythm monitoring – with...
The Adagio Medical iCLAS cryoablation system is commercial in Europe and is also part of an ongoing FDA IDE trial in the U.S. #HRS21
News | Atrial Fibrillation | August 09, 2021
August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for...
Rhythm Therapeutics gene, stem cell, therapy for atrial fibrillation.
News | Atrial Fibrillation | April 19, 2021
April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm Therape
Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

Medtronic's DiamondTemp Ablation (DTA) system is FDA cleared to treat patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

News | Atrial Fibrillation | January 29, 2021
January 29, 2021 — The U.S.
Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Patients with atrial fibrillation are at far greater risk of a catastrophic COVID outcomes, so steps should be taken to reduce AFib risks in addition to precautions against COVID like making, hand washing and social distancing. Images include an electromap from an AF ablation procedure and a COVID-19 from the CDC. 

Feature | Atrial Fibrillation | January 27, 2021 | By John D. Day, M.D., T. Jared Bunch, M.D., and Matthew D. LaPlante
In our most challenging and distressing days, it is nice to think about a post-COVID-19 world. 
ECG with paroxysm correct form of atrial flutter. Getty Images

ECG with paroxysm correct form of atrial flutter. Getty Images

News | Atrial Fibrillation | December 23, 2020
December 23, 2020 — The American College of Cardiology (ACC) and the American Heart Association (AHA) has made two up